Amylin Pharmaceuticals, Inc., Eli Lilly and Company Diabetes Drug Faces Crucial FDA Decision

Dow Jones -- After years of anticipation, a long-acting version of diabetes drug Byetta, sold by Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY), faces a crucial Food and Drug Administration approval decision this week.

Back to news